Natco Pharma Limited reported a 25% decline in consolidated net profit to ?14,185 million for the financial year ended March 31, 2026, compared to ?18,834 million in the previous year. Total revenue for the year stood at ?43,759 million, down from ?47,840 million in FY25. The company's board approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. Following the results announcement, the company held an earnings conference call on May 29, 2026, to discuss the performance. The transcript of this call, filed under Regulation 30 of the…